Literature DB >> 6770752

Pharmacokinetics of ceftizoxime in animals after parenteral dosing.

T Murakawa, H Sakamoto, S Fukada, S Nakamoto, T Hirose, N Itoh, M Nishida.   

Abstract

The pharmacokinetic profile of ceftizoxime was studied in mice, rats, dogs, and monkeys given the drug in a single parenteral dose. The serum data after an intravenous injection were analyzed by the two-compartment open model. Cefotiam, cefmetazole, cefotaxime, and cefamandole were used as reference drugs. High concentrations of ceftizoxime were attained in the sera of all test animals and in the tissues of rats after parenteral dosing. The serum concentrations of ceftizoxime were higher than those of the other antibiotics in large animals (dogs and monkeys), but were lower in small animals (mice and rats). About 80% of ceftizoxime was excreted unchanged in the 24-h urine of all species tested. The biliary excretion of ceftizoxime was low: 3.7% in rats and 0.59% in dogs. However, therapeutically significant concentrations of ceftizoxime were found in the bile of dogs. Ceftizoxime was stable in biological fluids such as serum, urine, and tissue homogenates, but cefotaxime was unstable in rat tissue homogenates. Binding of ceftizoxime to serum protein in all species was the lowest of all the antibiotics: 31% for humans, 17% for dogs, and 32% for rats.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770752      PMCID: PMC283751          DOI: 10.1128/AAC.17.2.157

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans.

Authors:  B E Cabana; D R van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1976-08       Impact factor: 5.191

2.  Cefuroxime: human pharmacokinetics..

Authors:  R D Foord
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

3.  Cefazolin, a new semisynthetic cephalosporin antibiotic. II. In vitro and in vivo antimicrobial activity.

Authors:  M Nishida; T Matsubara; T Murakawa; Y Mine; Y Yokota
Journal:  J Antibiot (Tokyo)       Date:  1970-03       Impact factor: 2.649

4.  Chromatographic assay of mixed penicillins, ampicillin and cloxacillin in body fluids.

Authors:  T Murakawa; Y Waki; M Nishida; R Fuji; M Konno
Journal:  J Antibiot (Tokyo)       Date:  1970-05       Impact factor: 2.649

5.  Ion-pair extraction and high-speed liquid chromatography of cephalothin and deacetylcephalothin in human serum and urine.

Authors:  M J Cooper; M W Anders; B L Mirkin
Journal:  Drug Metab Dispos       Date:  1973 Sep-Oct       Impact factor: 3.922

6.  In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative.

Authors:  M Nishida; T Murakawa; T Kamimura; N Okada; H Sakamoto; S Fukada; S Nakamoto; Y Yokota; K Miki
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

7.  Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  T Kamimura; Y Matsumoto; N Okada; Y Mine; M Nishida; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

  7 in total
  14 in total

1.  Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics.

Authors:  S Tawara; S Matsumoto; T Kamimura; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.

Authors:  J Mordenti
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

3.  High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

Authors:  R H Barbhaiya; S T Forgue; W C Shyu; E A Papp; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

4.  Pharmacokinetics of the cephalosporin SM-1652 in mice, rats, rabbits, dogs, and rhesus monkeys.

Authors:  H Matsui; K Yano; T Okuda
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

5.  Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals.

Authors:  M Komiya; Y Kikuchi; A Tachibana; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

6.  Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.

Authors:  J G Christenson; K K Chan; R Cleeland; B Dix-Holzknecht; H H Farrish; I H Patel; A Specian
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

7.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

8.  Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.

Authors:  Lorna E T Stearne; Doret van Boxtel; Nicole Lemmens; Wil H F Goessens; Johan W Mouton; Inge C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  beta-Lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses.

Authors:  M T Fields; B L Herndon; D M Bamberger
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

10.  Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.

Authors:  S T Forgue; W C Shyu; C R Gleason; K A Pittman; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.